SUNNYVALE, California, September 10 /PRNewswire/ --

- TV feature from Telegent used by Latin American journalists at 2008 Beijing Games

Telegent Systems, the company that makes television mobile with its high-performance single-chip mobile TV solutions, today announced that handsets incorporating Telegent's mobile TV technology will soon be available to consumers in Latin America, expanding the global reach of manufacturers that have incorporated the free-to-air TV feature into their handsets. The handsets will provide access to all TV broadcast channels throughout the region, enabling consumers to stay abreast of news, sports and favorite TV programs no matter where they are, and with no investment in infrastructure required by operators or broadcasters.

BRIDGEWATER, New Jersey, September 10 /PRNewswire/ --

- Original Briefing Papers Used by NICE to Shape Its New Cost-Effectiveness Guidelines Offer Unique and Timely Insight for Honing Manufacturer Submissions

SAN FRANCISCO, California (CTIA IT), September 10 /PRNewswire/ -- Acision, the world's leading messaging company, announces the launch of the Acision Innovation Network, a partnership-based ecosystem that will enable the global communications community to collaborate on the creation of new applications and services to advance the way the world communicates.

PARIS, September 10 /PRNewswire/ --

- Abstracts 185 and 1112

Sanofi-aventis, a world leader in diabetes care, announced results from two randomized clinical studies presented at the European Association for the Study of Diabetes (EASD) 44th Annual Meeting demonstrating that the "basal plus" insulin strategy with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and APIDRA(R) once daily (prandial insulin) (insulin glulisine (rDNA origin) injection) administered at the main meal (defined by the highest postprandial blood glucose level) improve blood glucose levels in patients with type 2 diabetes after basal insulin optimisation.

PARIS, September 10 /PRNewswire/ --

- Abstracts 186 and 1003

Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin regimen with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and rapid-acting APIDRA(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes. Both studies, GINGER (a clinical trial) and LACE (real life patient data) confirmed the superior efficacy of LANTUS(R)/APIDRA(R) basal-bolus therapy when compared to pre-mixed insulin regimens.

DES PLAINES, Illinois, September 10 /PRNewswire/ --

- Technology will convert cellulosic biomass to bio-oil for industrial heating, power generation and transportation fuels

UOP LLC, a Honeywell (NYSE: HON) company, announced today that it has signed a letter of intent with Ensyn Corp to form a joint venture to offer technology and equipment to convert second-generation biomass into oil for power generation, heating fuel and eventually for conversion into transportation fuels. UOP and Ensyn expect to finalize terms for the venture in the fourth quarter of 2008.